BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $140,574.72 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 5,632 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72. Following the transaction, the insider now directly owns 45,860 shares of the company's stock, valued at $1,144,665.60. This represents a 10.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total value of $68,560.80.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total value of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total value of $6,484.80.

BioLife Solutions Trading Down 0.3 %

Shares of NASDAQ BLFS traded down $0.07 during midday trading on Friday, reaching $24.99. 569,608 shares of the stock were exchanged, compared to its average volume of 350,123. The stock has a 50 day moving average price of $26.40 and a 200-day moving average price of $25.48. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.17 billion, a P/E ratio of -23.58 and a beta of 2.04. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same quarter last year, the firm earned ($0.21) earnings per share. Equities research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. State Street Corp increased its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider's stock valued at $21,107,000 after purchasing an additional 18,473 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider's stock valued at $487,000 after purchasing an additional 5,638 shares in the last quarter. Barclays PLC grew its holdings in shares of BioLife Solutions by 20.1% during the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider's stock worth $1,613,000 after purchasing an additional 10,803 shares during the period. Finally, D.A. Davidson & CO. acquired a new stake in BioLife Solutions during the 3rd quarter worth approximately $1,018,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BLFS has been the topic of a number of recent analyst reports. StockNews.com raised shares of BioLife Solutions from a "sell" rating to a "hold" rating in a research note on Wednesday. Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. Benchmark reiterated a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. Finally, HC Wainwright boosted their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.